ReviewCancers2021
Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Diagnostic accuracy of methylatedFrontiers in endocrinology · 2025Pooled it
- Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.Journal for immunotherapy of cancer · 2022Trial
- Circulating tumor DNA as a predictive biomarker for prognosis in hepatocellular carcinoma: a systematic review and meta-analysis.Journal of the National Cancer Center · 2026Article
- Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care.Cancer cell international · 2026Review
- Immune escape in portal vein tumor thrombus: an intravascular tumor-immune niche framework for hepatocellular carcinoma.Frontiers in immunology · 2026Review
- Human leukocyte antigen-G in hepatocellular carcinoma driven by chronic viral hepatitis or steatotic liver disease.Scientific reports · 2025Article
- An Artificial Intelligence Pipeline for Hepatocellular Carcinoma: From Data to Treatment Recommendations.International journal of general medicine · 2025Review
- Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2024Review
- Unveiling the Influence of AI Predictive Analytics on Patient Outcomes: A Comprehensive Narrative Review.Cureus · 2024Review
- Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.Frontiers in immunology · 2024Review
- Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review).Experimental and therapeutic medicine · 2023Review
- Peripheral blood-based cell signature indicates response to interstitial brachytherapy in primary liver cancer.Journal of cancer research and clinical oncology · 2023Article
- Article
- Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.BMC cancer · 2023Article
- Tracking of trastuzumab resistance in patients with HER2-positive metastatic gastric cancer by CTC liquid biopsy.American journal of cancer research · 2023Article
- European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Review
- Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows.World journal of gastrointestinal oncology · 2022Review
- Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the deadliest cancer types worldwide. HCC is often diagnosed at a late stage when the therapeutic options are very limited. However, even at the earlier stages, the best treatment is liver transplantation, surgical resection or ablation. Surgical resection and ablation may carry a high risk of tumor recurrence. The recent introduction of immunotherapies resulted in clinical responses for a subgroup of patients, but there were still no effective predictive markers for response to immunotherapy or for recurrence after surgical therapy. The identification of biomarkers that could correlate and predict response or recurrence would require close monitoring of the patients throughout and after the completion of treatment. However, this would not be performed efficiently by repeated and invasive tissue biopsies. A better approach would be to use liquid biopsies including circulating tumor DNA (ctDNA), circulating RNA (e.g., microRNAs), circulating tumor cells (CTC) and extracellular vesicles (EVs) (e.g., exosomes) for disease monitoring in a non-invasive manner. In this review, we discuss the currently available technology that can enable the use of liquid biopsy as a diagnostic and prognostic tool. Moreover, we discuss the opportunities and challenges of the clinical application of liquid biopsy for immunotherapy of HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.